Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study)
ContributorsAymon, Romain Victor Rudolf![orcid](assets/images/orcid.png)
; Mongin, Denis![orcid](assets/images/orcid.png)
; Bergstra, Sytske Anne![orcid](assets/images/orcid.png)
; Choquette, Denis; Codreanu, Catalin; De Cock, Diederik; Dreyer, Lene; Elkayam, Ori; Huschek, Doreen; Hyrich, Kimme L![orcid](assets/images/orcid.png)
; Iannone, Florenzo![orcid](assets/images/orcid.png)
; Inanc, Nevsun![orcid](assets/images/orcid.png)
; Kearsley-Fleet, Lianne![orcid](assets/images/orcid.png)
; Koca, Suleyman Serdar; Kvien, Tore K; Leeb, Burkhard F; Lukina, Galina; Nordström, Dan C; Pavelka, Karel; Pombo-Suarez, Manuel![orcid](assets/images/orcid.png)
; Rodrigues, Ana![orcid](assets/images/orcid.png)
; Rotar, Ziga; Strangfeld, Anja![orcid](assets/images/orcid.png)
; Verschueren, Patrick![orcid](assets/images/orcid.png)
; Westermann, Rasmus; Zavada, Jakub; Courvoisier, Delphine![orcid](assets/images/orcid.png)
; Finckh, Axel![orcid](assets/images/orcid.png)
; Lauper, Kim![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
Published inAnnals of the rheumatic diseases, vol. 83, no. 4, p. 421-428
Publication date2024-04-08
First online date2023-12-08
Abstract
Keywords
- Antirheumatic Agents
- Arthritis, Rheumatoid
- Biological Therapy
- Epidemiology
- Antirheumatic Agents / therapeutic use
- Arthritis, Rheumatoid / drug therapy
- Azetidines
- Humans
- Janus Kinase Inhibitors / therapeutic use
- Purines
- Pyrazoles
- Sulfonamides
- Treatment Outcome
- Tumor Necrosis Factor Inhibitors / therapeutic use
- Tumor Necrosis Factor-alpha
- Baricitinib
- Janus Kinase Inhibitors
- Tumor Necrosis Factor Inhibitors
Affiliation
Funding
- AbbVie -
- Eli Lilly and Company -
- Pfizer -
- Galapagos -
Citation (ISO format)
AYMON, Romain Victor Rudolf et al. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study). In: Annals of the rheumatic diseases, 2024, vol. 83, n° 4, p. 421–428. doi: 10.1136/ard-2023-224670
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
- PID : unige:178520
- DOI : 10.1136/ard-2023-224670
- PMID : 38071508
- PMCID : PMC10958307
Commercial URLhttps://ard.bmj.com/lookup/doi/10.1136/ard-2023-224670
ISSN of the journal0003-4967